|
Male gender, n (%)
|
367 (52.7)
|
24 (70.6)
|
0.04
|
|
Age, years, ≥ 67, n (%)
|
373 (53.6)
|
23 (67.6)
|
0.11
|
|
BMI, kg/m2 ≥ 26, n (%)
|
285 (51.4)
|
14 (42.4)
|
0.32
|
|
Presence of diabetes, n (%)
|
89 (12.8)
|
10 (29.4)
|
0.006
|
|
CTP B class, n (%)
|
72 (10.3)
|
10 (29.4)
|
0.001
|
|
HCV genotype 1, n (%)
|
524 (76.2)
|
28 (82.4)
|
0.41
|
|
24 weeks treatment duration, n (%)
|
311 (44.6)
|
19 (55.9)
|
0.19
|
|
Baseline HCV-RNA, UI/ml, ≥ 1 × 106, n (%)
|
381 (54.7)
|
13 (38.2)
|
0.06
|
|
Liver stiffness, kPa ≥ 20, n (%)
|
176 (49.7)
|
24 (72.7)
|
0.01
|
|
SVR12, n (%)
|
682 (97.8)
|
32 (94.1)
|
0.16
|
|
DAA-SOF based, n (%)
|
555 (79.6)
|
30 (88.2)
|
0.31
|
|
DAA-RBV included, n (%)
|
535 (76.8)
|
15 (44.1)
|
< 0.0001
|
|
DAA-SOF + RBV, n (%)
|
438 (63.0)
|
12 (35.3)
|
0.001
|
|
DAA-SOF without RBV, n (%)
|
113 (16.2)
|
18 (52.9)
|
< 0.0001
|
